At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 25 enrolled
Drug / intervention
Toripalimabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Neoadjuvant PD-1 Blockade Combined With Chemotherapy Followed by Concurrent Immunoradiotherapy for Locally Advanced Anal Canal Squamous Carcinoma Patients
In Brief
A Phase 2 clinical trial evaluating Toripalimab for Anal Canal Cancer and 5 related conditions. Completed, enrolled 25 participants across 1 site.
Detailed Summary
Locally Advanced Anal Canal Squamous Carcinoma Patients will be enrolled and given four cycles of neoadjuvant PD-1 antibody toripalimab combined with docetaxol and cisplatin, followed by radiotherapy and two cycles of concurrent toripalimab. Treatment outcomes and toxicities will be evaluated.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnal Canal Cancer, Anal Squamous Cell Carcinoma, Anal Cancer, Anal Canal Cancer Stage I, Anal Canal Cancer Stage II, Anal Canal Cancer Stage III
CountriesChina
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedSep 2021
Enrollment StartOct 2021
Primary CompletionJun 2024
Study CompletionNov 2024
TodayJul 2026
First PostedSep 29, 2021
Enrollment StartOct 27, 2021
Primary CompletionJun 21, 2024
Study CompletionNov 27, 2024
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 4.8 years ago
Interventions
Toripalimabdrug
Four cycles of neoadjuvant PD-1 antibody toripalimab combined with docetaxol and cisplatin, followed by radiotherapy and two cycles of concurrent toripalimab.